1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

• Status: Completed
• Trial end date: 2020-10-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Treatments: Etiracetam; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Adult (>18 years of age and older) patients who have or will have undergone surgical resection or biopsy of a supratentorial brain tumor and are able to consent for themselves.

• Able to be randomized prior to or up to 48 hours after surgery.

Exclusion Criteria:

• No known history of seizure activity.

• Pregnant or breastfeeding.

• Renal dysfunction (CrCl < 30ml/min).

• Beck's Depression Inventory (BDI) ≥14

• Allergy to levetiracetam.